Moderna Seeks FDA Approval For COVID-19 Booster Shot

74
Comment
Favorite

Moderna Seeks FDA Approval For COVID-19 Booster Shot

Benzinga2021-09-02

Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster. What Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

KS_Lee
·2021-09-02
Probably will break 400 today and if approved the booster likely to retest recent all time high.
Reply
1
Report
Fold Replies
- Littlenoobie:
  Ok
  2021-09-02
  Reply
  Report
ElginLow
·2021-09-02
Nice
Reply
3
Report
YauDK
·2021-09-02
Oh ye ye pls like and comment
Reply
2
Report
TeikLeong
·2021-09-02
Like
Reply
3
Report
Fold Replies
- ChowCCJ:
  Done
  2021-09-02
  Reply
  Report
Wee93
·2021-09-02
Good
Reply
1
Report
CSL1m
·2021-09-02
Like
Reply
4
Report
Fold Replies
- Footixx:
  ?
  2021-09-02
  Reply
  Report
lyokel
·2021-09-02
Ok
Reply
3
Report
DesmondChin
·2021-09-02
Have you settled the containment issues at Japan?
Reply
3
Report
Fold Replies
- lyokel:
  haha
  2021-09-02
  Reply
  Report
leekanghao
·2021-09-02
Here we go again
Reply
4
Report
JKJKJK
·2021-09-02
Pls help to like
Reply
6
Report
Fold Replies
- RonnieO:
  Ok
  2021-09-02
  Reply
  Report
- damienng:
  o
  2021-09-02
  Reply
  Report
- AtwoZ:
  Done
  2021-09-02
  Reply
  Report
assassinyj
·2021-09-02
?
Reply
7
Report
Fold Replies
- assassinyj:
  Haha
  2021-09-02
  Reply
  Report
Jjjjia
·2021-09-02
Like pls
Reply
7
Report
aliciatng
·2021-09-02
Like tq
Reply
6
Report
Fold Replies
- Jjjjia:
  Done
  2021-09-02
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1188874540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-02 16:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188874540","market":"us","top_or_hot":-1,"title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","media":"Benzinga","content":"<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Source Link</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","article_id":"1188874540","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","pubTimestamp":1630571264,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳寻求美国食品和药物管理局批准新冠肺炎强化注射","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":812850468,"gmtCreate":1630575715854,"gmtModify":1676530344880,"author":{"id":"3579578865458065","authorId":"3579578865458065","name":"KS_Lee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Probably will break 400 today and if approved the booster likely to retest recent&nbsp;all time high.&nbsp;","listText":"Probably will break 400 today and if approved the booster likely to retest recent&nbsp;all time high.&nbsp;","text":"Probably will break 400 today and if approved the booster likely to retest recent all time high.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812850468","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729236,"gmtCreate":1630575924234,"gmtModify":1631892765407,"authorId":4087110853440910,"author":{"id":4087110853440910,"authorId":4087110853440910,"name":"Littlenoobie","avatar":"https://static.tigerbbs.com/02d08b3ef6fcfd7e08dcc2b8ebf67301","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812850468,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":812850874,"gmtCreate":1630575675198,"gmtModify":1676530344864,"author":{"id":"3578313543552744","authorId":"3578313543552744","name":"ElginLow","avatar":"https://static.tigerbbs.com/44d66a2d7ac712e903ddee8420e88c27","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812850874","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812829347,"gmtCreate":1630574897789,"gmtModify":1676530344669,"author":{"id":"3580072870029753","authorId":"3580072870029753","name":"YauDK","avatar":"https://static.tigerbbs.com/4e00c10df4000c04392220903422d15f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oh ye ye pls like and comment&nbsp;","listText":"Oh ye ye pls like and comment&nbsp;","text":"Oh ye ye pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812829347","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812882706,"gmtCreate":1630573556005,"gmtModify":1676530344279,"author":{"id":"3581504913688063","authorId":"3581504913688063","name":"TeikLeong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812882706","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5729030,"gmtCreate":1630574088814,"gmtModify":1663233276931,"authorId":3575375342391732,"author":{"id":3575375342391732,"authorId":3575375342391732,"name":"ChowCCJ","avatar":"https://static.tigerbbs.com/bc5fafdf3c6b7c87a4217f2f73a89adb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812882706,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":812888523,"gmtCreate":1630573281262,"gmtModify":1676530344224,"author":{"id":"3559122008797693","authorId":"3559122008797693","name":"Wee93","avatar":"https://static.tigerbbs.com/68f347275fc58792610a1f69df23fb2f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812888523","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812889502,"gmtCreate":1630573104506,"gmtModify":1676530344160,"author":{"id":"3568421726936497","authorId":"3568421726936497","name":"CSL1m","avatar":"https://static.tigerbbs.com/49565bb8d6cdc108dcbc0e1cb24f57f7","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812889502","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728917,"gmtCreate":1630573242398,"gmtModify":1663233276927,"authorId":3572228950547010,"author":{"id":3572228950547010,"authorId":3572228950547010,"name":"Footixx","avatar":"https://static.tigerbbs.com/286a694c51da40f13325f2f7cd6b8851","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812889502,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":812812911,"gmtCreate":1630572634533,"gmtModify":1676530344029,"author":{"id":"3563941452424650","authorId":"3563941452424650","name":"lyokel","avatar":"https://community-static.tradeup.com/news/a0bd3f0fc07966cf561519ba8ef67d7e","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812812911","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812816535,"gmtCreate":1630572603327,"gmtModify":1676530344020,"author":{"id":"3578983795474363","authorId":"3578983795474363","name":"DesmondChin","avatar":"https://static.tigerbbs.com/b90cb6b6a6c328ac8d02a829e5e7c835","vip":1,"hat":"https://static.tigerbbs.com/46b6808e1ba3716fb9c53339adffa3c5","crmLevel":3,"crmLevelSwitch":1},"htmlText":"Have you settled the containment issues at Japan?&nbsp;","listText":"Have you settled the containment issues at Japan?&nbsp;","text":"Have you settled the containment issues at Japan?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812816535","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728821,"gmtCreate":1630572629190,"gmtModify":1663233278930,"authorId":3563941452424650,"author":{"id":3563941452424650,"authorId":3563941452424650,"name":"lyokel","avatar":"https://community-static.tradeup.com/news/a0bd3f0fc07966cf561519ba8ef67d7e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812816535,"type":1,"supId":0,"prevId":0,"content":"haha","text":"haha","html":"haha"}],"langContent":"EN"},{"id":812810685,"gmtCreate":1630572154847,"gmtModify":1676530343835,"author":{"id":"3583978426873835","authorId":"3583978426873835","name":"leekanghao","avatar":"https://static.tigerbbs.com/3c1122e49e06c919b85c00976e928d03","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Here we go again","listText":"Here we go again","text":"Here we go again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812810685","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812836083,"gmtCreate":1630571653042,"gmtModify":1676530343707,"author":{"id":"3581988841626176","authorId":"3581988841626176","name":"JKJKJK","avatar":"https://static.tigerbbs.com/882030abc3e0ffb1122b6a566ab01832","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls help to like","listText":"Pls help to like","text":"Pls help to like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/812836083","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728990,"gmtCreate":1630573706437,"gmtModify":1663233280037,"authorId":4088850777374920,"author":{"id":4088850777374920,"authorId":4088850777374920,"name":"RonnieO","avatar":"https://static.tigerbbs.com/1292a5981b699a40c70f37718afa2985","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5728723,"gmtCreate":1630571762821,"gmtModify":1631890338622,"authorId":3573522326711377,"author":{"id":3573522326711377,"authorId":3573522326711377,"name":"damienng","avatar":"https://static.tigerbbs.com/1f871cfd738787c8daf99ae3c46baf0f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"o","text":"o","html":"o"},{"id":5728722,"gmtCreate":1630571757799,"gmtModify":1631890338611,"authorId":3586254379286032,"author":{"id":3586254379286032,"authorId":3586254379286032,"name":"AtwoZ","avatar":"https://static.tigerbbs.com/7347da48f4f74369b5ff3a53a2e36a45","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812836083,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"}],"langContent":"EN"},{"id":812838948,"gmtCreate":1630571602984,"gmtModify":1676530343683,"author":{"id":"3570795138700824","authorId":"3570795138700824","name":"assassinyj","avatar":"https://static.tigerbbs.com/c5c10786bc09238ddcb1c4b89e9cfa6e","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"?&nbsp;","listText":"?&nbsp;","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812838948","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728706,"gmtCreate":1630571607969,"gmtModify":1663233276437,"authorId":3570795138700824,"author":{"id":3570795138700824,"authorId":3570795138700824,"name":"assassinyj","avatar":"https://static.tigerbbs.com/c5c10786bc09238ddcb1c4b89e9cfa6e","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812838948,"type":1,"supId":0,"prevId":0,"content":"Haha","text":"Haha","html":"Haha"}],"langContent":"EN"},{"id":812839264,"gmtCreate":1630571441658,"gmtModify":1676530343628,"author":{"id":"4087709618925430","authorId":"4087709618925430","name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812839264","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812830745,"gmtCreate":1630571402687,"gmtModify":1676530343613,"author":{"id":"3572214398550610","authorId":"3572214398550610","name":"aliciatng","avatar":"https://static.tigerbbs.com/c4b23ee891a1061c7907495a9c7da890","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like tq","listText":"Like tq","text":"Like tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/812830745","repostId":1188874540,"repostType":4,"repost":{"id":"1188874540","pubTimestamp":1630571264,"share":"https://www.laohu8.com/m/news/1188874540?lang=&edition=full","pubTime":"2021-09-02 16:27","market":"us","language":"en","title":"Moderna Seeks FDA Approval For COVID-19 Booster Shot","url":"https://stock-news.laohu8.com/highlight/detail?id=1188874540","media":"Benzinga","summary":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.","content":"<p><b>Moderna Inc</b>&nbsp;is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.</p>\n<p><b>What Happened:</b>The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.<b>Food and Drug Administration</b>&nbsp;for evaluation of a booster dose of its vaccine at the 50 microgram dose level.</p>\n<p>“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.</p>\n<p>The usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.</p>\n<p><b>Why It Matters:</b>Moderna said it expects to submit data to the&nbsp;<b>European Medicines Agency</b>(EMA) and other regulatory authorities globally in the “coming days.”</p>\n<p>In April, Moderna posted an update to its vaccine program, which included an examination of the&nbsp;vaccine’s effectiveness at the six-month mark.</p>\n<p>At the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.</p>\n<p>Moderna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.</p>\n<p>“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.</p>\n<p>Last month, the FDA approved a booster dose of mRNA COVID-19 vaccines for&nbsp;immunocompromised individuals&nbsp;who have already received two shots citing the need for extra protection.</p>\n<p>On Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots&nbsp;for the general population is limited.</p>\n<p><b>Price Action:</b>On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Seeks FDA Approval For COVID-19 Booster Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Seeks FDA Approval For COVID-19 Booster Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-02 16:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/09/22772682/moderna-seeks-fda-approval-for-covid-19-booster-shot","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188874540","content_text":"Moderna Inc is pushing ahead for authorization of a third shot of its COVID-19 vaccine as a booster.\nWhat Happened:The Massachusetts-based company said in a statement Wednesday that it had initiated its submission to the U.S.Food and Drug Administration for evaluation of a booster dose of its vaccine at the 50 microgram dose level.\n“Our submission is supported by data generated with the 50 µg dose of our COVID-19 vaccine, which shows robust antibody responses against the Delta variant,” said Stéphane Bancel, Chief Executive Officer of Moderna.\nThe usual dose for Moderna’s vaccinecontains100 micrograms of mRNA per shot.\nWhy It Matters:Moderna said it expects to submit data to the European Medicines Agency(EMA) and other regulatory authorities globally in the “coming days.”\nIn April, Moderna posted an update to its vaccine program, which included an examination of the vaccine’s effectiveness at the six-month mark.\nAt the time, the company said that its COVID-19 vaccine provided over 90% effectiveness against all cases after the second dose.\nModerna said on Wednesday that the Phase 2 study of mRNA-1273 was amended to offer a booster dose at the 50 microgram dose to interested participants 6 months after their second dose.\n“Neutralizing antibody titers had waned significantly prior to boosting at approximately 6 months. A booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark,” the company said.\nLast month, the FDA approved a booster dose of mRNA COVID-19 vaccines for immunocompromised individuals who have already received two shots citing the need for extra protection.\nOn Monday, U.S. Centers for Disease Control and Prevention scientist Sara Oliver said at an advisory group meeting thatdata required to evaluate booster shots for the general population is limited.\nPrice Action:On Wednesday, Moderna shares closed nearly 3.5% higher at $389.94 in the regular session and rose 0.81% higher to $393.10 in the after-hours trading.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5728679,"gmtCreate":1630571454383,"gmtModify":1663233276051,"authorId":4087709618925430,"author":{"id":4087709618925430,"authorId":4087709618925430,"name":"Jjjjia","avatar":"https://static.tigerbbs.com/25215d9b4b22838734cba07948cafe46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":812830745,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":74,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}